SCHEMBL5537590

SCHEMBL5537590

Cc1noc(-c2ccccc2)c1NC(=O)N(C)C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.56
ABCC1 P33527 3/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 1/20 0.51
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LPAR1 Q92633 2/20 0.49
LPAR3 Q9UBY5 1/20 0.49
SLC6A9 P48067 1/20 0.48
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.43
S1PR1 P21453 2/20 0.42
KMT2A Q03164 1/20 0.42
S1PR3 Q99500 1/20 0.42
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
SLCO1B1 Q9Y6L6 2/20 0.41
ABCC3 O15438 1/20 0.41
ABCC4 O15439 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22256920 0.89 ATM (0.44) ATMABCC1RAB9ANPC1MAPT
SCHEMBL22257222 0.88 TRPV1 (0.45) ATMABCC1RAB9ANPC1MAPT
SCHEMBL22257004 0.85 SLCO1B1 (0.54) ATMABCC1RAB9ANPC1MAPT
SCHEMBL5539079 0.82 ATM (0.56) ATMABCC1RAB9ANPC1MAPT
SCHEMBL24287636 0.81 ATM (0.38) ATMABCC1RAB9ANPC1MAPT
SCHEMBL22256587 0.80 SLCO1B1 (0.68) ATMABCC1RAB9ANPC1MAPT
SCHEMBL4200801 0.79 KDM4E (0.58) RAB9ANPC1MAPTKDM4ELPAR1
SCHEMBL5772191 0.77 LPAR1 (0.57) RAB9AMAPTKDM4ELPAR1LPAR3
SCHEMBL4035675 0.77 MAPT (0.67) MAPTKDM4ELPAR1LPAR3ALDH1A1
SCHEMBL22256922 0.75 SLCO1B1 (0.55) ATMMAPTLPAR1LPAR3SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 ATM 2072/4885ABCC1 2977/4885RAB9A 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.